Ben Wang

Ben Wang has a diverse and extensive work experience. Ben is the co-founder of Cytokind Inc., a company they started in 2020. Prior to that, they co-founded Chimera Bioengineering in 2015, where they focused on developing engineered cell therapies for cancer patients. Ben also co-founded Svaya Nanotechnologies, Inc. in 2008, working on nanotechnology-related projects until 2015. Ben has also worked as a Graduate Researcher at MIT from 2003 to 2007, and as an R&D Engineer - Microfluidics at Caliper Life Sciences from 1998 to 2002. Additionally, they had roles at Bell Biosystems as a Helper from 2011 to 2019, and at Prospect Bio as a Helper from 2014 to 2019. Ben briefly worked as an Entrepreneur in Residence (EIR) at start x in 2015. Overall, Ben's work experience demonstrates their expertise in biotechnology, engineering, and entrepreneurship.

Ben Wang has a strong education history in Chemical Engineering. Ben obtained a Bachelor of Science degree in Chemical Engineering from Stanford University, where they studied from 1994 to 1998. Following their undergraduate studies, they pursued further education at the Massachusetts Institute of Technology, where they completed their PhD in Chemical Engineering from 2002 to 2007.